Voyager Therapeutics

voyagertherapeutics.com

Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.